Orphazyme A/S
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Kim Stratton
- Full Time Employees
- 180
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- Ole MaalOees Vej 3 Copenhagen Denmark 2200
- IPO Date
- Sep 4, 2020
- CIK
- 0001764791
- Website
- orphazyme.com
- Similar Companies
- Business
- Strategic Partners A/S (formerly Orphazyme A/S) is a Danish investment company that enters into strategic partnerships with businesses demonstrating significant potential, taking an active ownership role to create value through its expertise; it also invests in equity capital, properties, and other assets to generate returns. Founded in 2009 and headquartered in Herlev, Denmark, the company divested substantially all of its biopharmaceutical assets and business activities, including the development of arimoclomol for orphan diseases such as Niemann-Pick disease type C, to Zevra Therapeutics (formerly KemPharm) in May 2022 for approximately $18 million in cash and assumed liabilities. A new board and management took over in May 2023, followed by a strategic shift with the approval of a new corporate purpose, name change from Orphazyme A/S to Strategic Partners A/S in October 2024, and recent investments including a stake in CombiGene AB (sold in January 2025 near acquisition cost) and ongoing exploration of additional partnerships.
Orphazyme Announces Publication of 2022 Financial Results and Annual Report
Orphazyme reports financial results in Interim Report First Half 2022
Orphazyme Announces Publication of 2021 Financial Results and Annual Report
Orphazyme completes sale of substantially all of its assets and business activities to KemPharm
Orphazyme A/S under In-Court-Restructuring to sell substantially all of its assets and business activities to KemPharm, Inc.
Orphazyme announces update on in-court restructuring proceedings
Orphazyme Withdraws European Application For Arimoclomol, Initiates Delisting Of Its ADSs
Dear ORPH Stock Fans, Mark Your Calendars for March 31
Orphazyme announces withdrawal of European Marketing Authorisation Application for arimoclomol for the treatment of Niemann-Pick disease type C
Orphazyme A/S has filed for voluntary delisting of ADSs
Notice of in-court restructuring proceedings of Orphazyme A/S
Orphazyme Calls For Court-Mediated Restructuring, Lays Off 50% Workforce
Commencement of in-court restructuring of Orphazyme A/S
Anders Vadsholt takes over as CEO of Orphazyme
CytRx Comments on Orphazyme's Update on European Union Regulatory Review of Arimoclomol in Niemann-Pick Disease Type C
EMA's Advisory Committee Does Not Back Orphazyme's Arimoclomol Application
Orphazyme announces update on regulatory review of arimoclomol in the European Union
Orphazyme (ORPH) Up on Plans of NDA Resubmission for Rare Drug
CytRx Highlights Orphazyme's Update on Planned NDA Resubmission for Arimoclomol in Niemann-Pick Disease Type C
Trading Penny Stocks? Top Stock Market News for February 11th, 2022